•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A09010 Summary:

BILL NOA09010A
 
SAME ASSAME AS S06758-A
 
SPONSORRosenthal
 
COSPNSR
 
MLTSPNSR
 
Amd §§3331 & 3309, Pub Health L
 
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
Go to top

A09010 Text:



 
                STATE OF NEW YORK
        ________________________________________________________________________
 
                                         9010--A
 
                               2025-2026 Regular Sessions
 
                   IN ASSEMBLY
 
                                     August 13, 2025
                                       ___________
 
        Introduced  by  M.  of  A.  ROSENTHAL  --  read once and referred to the
          Committee on Health -- recommitted  to  the  Committee  on  Health  in
          accordance  with Assembly Rule 3, sec. 2 -- committee discharged, bill
          amended, ordered reprinted as amended and recommitted to said  commit-
          tee

        AN  ACT to amend the public health law, in relation to requiring practi-
          tioners  to  discuss  certain  risks  with  a  patient  who  is  being
          prescribed a controlled substance or an opioid analgesic
 
          The  People of the State of New York, represented in Senate and Assem-
        bly, do enact as follows:
 
     1    Section 1. Subdivision 9 of section 3331 of the public health law,  as
     2  added by chapter 732 of the laws of 2022, is amended to read as follows:
     3    9.  (a)  When a patient seeks treatment for any [neuromusculoskeletal]
     4  condition that causes pain, where a practitioner  considers  [an  opioid
     5  treatment]  prescription  of  a schedule II controlled substance for the
     6  treatment of pain or any other opioid drug which is a prescription  drug
     7  for  acute  or  chronic  pain  and  again  prior  to  issuing  the third
     8  prescription of the course of treatment, the practitioner shall  consid-
     9  er,  discuss  with  the  patient  as  set forth in paragraph (b) of this
    10  subdivision, and, as appropriate, refer or prescribe  non-opioid  treat-
    11  ment  alternatives,  based  on  the practitioner's clinical judgment and
    12  following generally accepted national professional or  treatment  guide-
    13  lines, and consistent with patient preference and consent, before start-
    14  ing a patient on opioid treatment. For the purposes of this subdivision,
    15  non-opioid  treatment  alternatives  include,  but  are  not limited to:
    16  acupuncture, chiropractic, massage therapy,  physical  therapy,  occupa-
    17  tional  therapy,  cognitive  behavioral therapy, non-opioid medications,
    18  interventional treatments and non-clinical activities such as  exercise.
    19  The  practitioner  shall inform the patient that some treatments may not
    20  be covered by the patient's health coverage.
 
         EXPLANATION--Matter in italics (underscored) is new; matter in brackets
                              [ ] is old law to be omitted.
                                                                   LBD11164-03-5

        A. 9010--A                          2
 
     1    (b) A practitioner shall discuss with the patient,  or  the  patient's
     2  parent  or guardian if the patient is under eighteen years of age and is
     3  not an emancipated minor, the risks  associated  with  the  drugs  being
     4  prescribed, including but not limited to:
     5    (i)  the  risks of addiction and overdose associated with opioid drugs
     6  and the dangers of taking opioid drugs with alcohol, benzodiazepines and
     7  other central nervous system depressants;
     8    (ii) the reasons why the prescription is necessary;
     9    (iii) alternative treatments that may be available; and
    10    (iv) the risks associated with the use of the drugs being  prescribed,
    11  specifically  that  opioids  are  highly  addictive,  even when taken as
    12  prescribed, that there is a risk of developing a physical or  psycholog-
    13  ical  dependence  on  the  controlled  substance,  and that the risks of
    14  taking more opioids than prescribed, or  mixing  sedatives,  benzodiaze-
    15  pines   or  alcohol  with  opioids,  can  result  in  fatal  respiratory
    16  depression.
    17    (c) The department shall develop and make available  to  practitioners
    18  guidelines for the discussion required by this subdivision.
    19    (d)  The requirements of this subdivision shall not apply for patients
    20  being treated under any of the following circumstances:    treatment  of
    21  cancer;  hospice or other end-of-life care; post-surgery treatment imme-
    22  diately following a surgical procedure; or in a medical emergency.   For
    23  purposes  of this subdivision, "medical emergency" means an acute injury
    24  or illness that poses an immediate risk to a person's life or health.
    25    § 2. Paragraph (a) of subdivision 3 of  section  3309  of  the  public
    26  health  law  is  amended  by  adding a new subparagraph (vii) to read as
    27  follows:
    28    (vii) "Opioid analgesics" means the medicines buprenorphine, butorpha-
    29  nol,  codeine,  hydrocodone,  hydromorphone,  levorphanol,   meperidine,
    30  methadone,  morphine,  nalbuphine,  oxycodone, oxymorphone, pentazocine,
    31  propoxyphene as well as their brand names, isomers and combinations.
    32    § 3. Subdivision 7 of section 3309 of the public health law, as  added
    33  by chapter 803 of the laws of 2021, is amended to read as follows:
    34    7. [With] For the first opioid analgesic prescription [to a particular
    35  patient]  of  [an opioid of each] a calendar year that is greater than a
    36  one week's supply, for use in a setting other than a general hospital or
    37  nursing home under article twenty-eight  of  this  chapter  or  facility
    38  under  article  thirty-one  of the mental hygiene law, or when a practi-
    39  tioner is prescribing a controlled substance to a patient under the care
    40  of hospice as defined by section four thousand two of this chapter,  the
    41  prescriber  shall  counsel  the  patient  on  the risks of overdose, and
    42  prescribe an opioid antagonist when any of the  following  risk  factors
    43  are  present:  (a) a history of substance use disorder; (b) high dose or
    44  cumulative prescriptions that result in ninety morphine milligram equiv-
    45  alents or higher per day; (c) concurrent use of opioids and  benzodiaze-
    46  pine or nonbenzodiazepine sedative hypnotics.
    47    § 4. This act shall take effect immediately.
Go to top